Oral azacitidine

Phase 2

AAlliance for Clinical Trials in Oncology

Oral azacitidine is one of 27 therapeutic programs targeting Ann Arbor Stage III Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ann Arbor Stage III Diffuse Large B-Cell LymphomaActive, not recruiting

Angioimmunoblastic T-Cell LymphomaSuspended

T-Cell Large Granular Lymphocyte LeukemiaActive, not recruiting

Ann Arbor Stage III Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

Angioimmunoblastic T-Cell LymphomaPhase 2

Suspended

T-Cell Large Granular Lymphocyte LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Angioimmunoblastic T-Cell Lymphoma

#DrugCompanyPhaseTrials

Gemzar

Istodax

Treanda

AAzurity Pharmaceuticals

Oncovin

1 5

Adriamycin

Pfizer

Phase 2

1 6

Thalomid

Bristol-Myers Squibb

Phase 2

1 7

Neoral

Novartis

Phase 2

1 8

Fludara

Sanofi

Phase 2

1 9

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

NCT04799275

Clinical

Trials by Indication[1]

T-cell large granular lymphocyte leukemia1 trial

A Phase I/II Clinical Trial Evaluating CC-486 in Patients With Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)

Active, not recruiting·JJonathan Brammer·Preclinical·NCT05141682·11 enrolled

Ann Arbor Stage III Diffuse Large B-Cell Lymphoma1 trial

A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04799275·422 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Suspended·AAlliance for Clinical Trials in Oncology·Phase 2·NCT04803201·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Oral azacitidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral azacitidine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAlliance for Clinical Trials in Oncology

Oral azacitidine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

T-cell large granular lymphocyte leukemia1 trial

Ann Arbor Stage III Diffuse Large B-Cell Lymphoma1 trial

Angioimmunoblastic T-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News